Article
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
Lancet (London, England) - 20 Jun 2015
Hézode Christophe, Asselah Tarik, Reddy K Rajender, Hassanein Tarek, Berenguer Marina, Fleischer-Stepniewska Katarzyna, Marcellin Patrick, Hall Coleen, Schnell Gretja, Pilot-Matias Tami, Mobashery Niloufar, Redman Rebecca, Vilchez Regis A, Pol Stanislas
Abstract excerpt
BACKGROUND: Hepatitis C virus (HCV) genotype 4 accounts for about 13% of global HCV infections. Because interferon-containing treatments for genotype 4 infection have low efficacy and poor tolerability, an unmet need exists for effective all-oral regimens. We examined the efficacy and safety of an all-oral interferon-free regimen of ombitasvir, an NS5A inhibitor, and paritaprevir (ABT-450), an NS3/4A protease...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.